For anyone tracking cancer immunotherapy, the slow crawl of oncolytic virotherapy toward a second FDA approval reveals a striking gap between biological promise and clinical reality. A decade after T-VEC demonstrated that engineered viruses could selectively destroy tumors and recruit immune responses, the field has produced remarkably little follow-through — and understanding why matters for patients and researchers alike.
Replimune's RP1, a modified herpes simplex virus, is the frontrunner for what would become only the second oncolytic virus approved in a major market. Like T-VEC, RP1 targets melanoma via direct intratumoral injection — a delivery method that, while effective in accessible lesions, cannot reach metastatic disease scattered throughout the body. The FDA advisory committee review underscores just how narrow the therapeutic window remains. Field-wide obstacles include poorly designed pivotal trials, suboptimal timing of combination regimens with checkpoint inhibitors, tumor microenvironment factors such as hypoxia that limit viral replication, and a fundamental inability to deliver most oncolytic viruses systemically via intravenous routes without immune clearance.
The oncolytic virus landscape has been shaped by enormous early optimism that has consistently outpaced delivery. T-VEC's 2015 approval was expected to catalyze a wave of follow-on agents; instead, the field accumulated a string of Phase III failures. The core challenge is biological: the same immune system that oncolytic viruses are meant to activate also neutralizes them before they replicate sufficiently in tumors. Emerging strategies — neoadjuvant use before surgery to prime systemic immunity, smarter sequencing with PD-1 inhibitors, and engineered viruses with immunostimulatory payloads — suggest the field may be learning from its failures. A bladder-cancer oncolytic candidate nearing approval via intravesical delivery adds modest momentum. Still, the absence of a systemically deliverable agent remains the field's defining limitation. This article reads as a candid field audit: incremental progress, not breakthrough.